Vasculitis & polymyalgia rheumatica
Real-world outcomes of rituximab- and cyclophosphamide-based induction therapy regimens alone and in combination over 24 months in ANCA-associated vasculitis
Authors' conclusion
RTX alone was similarly effective to RTX/CYC combination and CYC-AZA therapy in AAV patients, including those with severe renal involvement.
Study context
- Population
- Patients with new-onset or relapsing organ- or life-threatening ANCA-associated vasculitis (AAV) (GPA n=97; MPA n=69), no previous rituximab (RTX) and/or CYC therapy, followed over 24 monthsGPA n=97
- Exposure
- RTX alone vs RTX/CYC induction, each followed by RTX maintenance, vs CYC-AZA
- Outcome
- Complete remission: absence of vasculitis activity with no concomitant GC therapy
- Follow-up
- 12 and 24 months
Methodological detailsreal-world data
- Real-world data
Main finding
As reported in the abstract
Complete remission · 12 months
P = 0.008
Observational data: associations, not effects.
Further findings
Complete remission · 24 months — RTX vs RTX/CYC · across RTX, RTX/CYC and CYC-AZA groups
P = 0.003
Remission with concomitant GC therapy at any time · 24 months — RTX vs RTX/CYC · across RTX, RTX/CYC and CYC-AZA groups
P = 0.097
- Relapse in GPA (subgroup) · RTX vs RTX/CYC
- P = 0.041
- Relapse in severe renal disease (subgroup) · RTX vs RTX/CYC · vs RTX/CYC and CYC-AZA
- P = 0.091
Relapse in GPA (subgroup)
- RTX alone associated with lower relapse rate vs RTX/CYC
Relapse in severe renal disease (subgroup)
- RTX alone comparably effective to RTX/CYC and CYC-AZA
Original publication
Real-world outcomes of rituximab- and cyclophosphamide-based induction therapy regimens alone and in combination over 24 months in ANCA-associated vasculitis. Clin Exp Rheumatol. Published 7 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →